Ind-Swift Laboratories Ltd

- Q1 FY 2026-27 standalone revenue: Rs 186.08 Cr - Q1 FY 2026-27 standalone net profit: Rs 24.44 Cr - Approved sale of 10 acres land for Rs 17.50 Cr - Land found unsuitable for plant setup as per regulatory needs

🔍 Financial Performance Highlights:

• Standalone revenue for quarter ended June 30, 2026: Rs 186.08 crore
• Other income: Rs 0.76 crore
• Total income: Rs 193.71 crore
• Expenses: Rs 161.05 crore
• Profit before tax: Rs 32.63 crore
• Profit after tax: Rs 24.44 crore
• Increased profitability versus same quarter last year

🛠 Land Sale Decision:

• 40 Bighas (approx. 10 acres) land located at Village Behra, Derabassi, Punjab approved for sale
• Sale consideration: Rs 17.50 crore
• Land was bought to setup finished dosage manufacturing but found unsuitable due to international regulatory requirements
• Sale completion expected over nine months subject to agreement

📈 Consolidated Financials:

• Consolidated revenue: Rs 199.10 crore
• Net profit after tax and exceptional items: Rs 24.68 crore

🤝 Auditor's Review:

• Unaudited but statutory auditor-reviewed financials with unqualified reports

🔍 Perception & Insights:

• Profit growth points to operational progress
• Sale reflects regulatory compliance and strategic asset reconsideration
• Transparent disclosures on financials and asset sale
• Important update on company’s regulatory and operational strategies

This information can help investors understand the company's quarterly performance and strategic decisions about its assets without speculating beyond disclosed facts.